ATE237338T1 - Allogene parakrine cytokine tumor impfstoffe - Google Patents

Allogene parakrine cytokine tumor impfstoffe

Info

Publication number
ATE237338T1
ATE237338T1 AT96945109T AT96945109T ATE237338T1 AT E237338 T1 ATE237338 T1 AT E237338T1 AT 96945109 T AT96945109 T AT 96945109T AT 96945109 T AT96945109 T AT 96945109T AT E237338 T1 ATE237338 T1 AT E237338T1
Authority
AT
Austria
Prior art keywords
cell line
tumor cell
allogene
tumor
tumor vaccines
Prior art date
Application number
AT96945109T
Other languages
English (en)
Inventor
Elizabeth M Jaffee
Drew M Pardoll
Hyam I Levitsky
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24318022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE237338(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE237338T1 publication Critical patent/ATE237338T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96945109T 1995-12-28 1996-12-26 Allogene parakrine cytokine tumor impfstoffe ATE237338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57970895A 1995-12-28 1995-12-28
PCT/US1996/020802 WO1997024132A1 (en) 1995-12-28 1996-12-26 Allogeneic paracrine cytokine tumor vaccines

Publications (1)

Publication Number Publication Date
ATE237338T1 true ATE237338T1 (de) 2003-05-15

Family

ID=24318022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945109T ATE237338T1 (de) 1995-12-28 1996-12-26 Allogene parakrine cytokine tumor impfstoffe

Country Status (7)

Country Link
EP (1) EP0869803B1 (de)
JP (1) JP2000502711A (de)
AT (1) ATE237338T1 (de)
AU (1) AU1355697A (de)
DE (1) DE69627527T2 (de)
ES (1) ES2191784T3 (de)
WO (1) WO1997024132A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620350D0 (en) 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
EP0893507A1 (de) 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
DE19832840C1 (de) * 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
GB9827103D0 (en) 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9911823D0 (en) * 1999-05-21 1999-07-21 Onyvax Ltd New vaccine formulations
CA2374294A1 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations - 2
WO2000071156A2 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations-3
WO2001075073A2 (en) 2000-04-01 2001-10-11 Onyvax Limited Prostate cell lines and their use
EP1441758A2 (de) * 2001-11-09 2004-08-04 MediGene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002025A1 (en) * 1988-11-02 1990-05-02 Geary W. Collins Continuous mammalian cell lines having monocyte-macrophage characteristics and their establishment in vitro
ES2080341T3 (es) * 1990-09-14 1996-02-01 Univ Johns Hopkins Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Also Published As

Publication number Publication date
EP0869803A1 (de) 1998-10-14
AU1355697A (en) 1997-07-28
DE69627527D1 (en) 2003-05-22
EP0869803B1 (de) 2003-04-16
DE69627527T2 (de) 2004-03-04
WO1997024132A1 (en) 1997-07-10
ES2191784T3 (es) 2003-09-16
JP2000502711A (ja) 2000-03-07

Similar Documents

Publication Publication Date Title
ATE237338T1 (de) Allogene parakrine cytokine tumor impfstoffe
ATE505206T1 (de) Verwendung des melanomdifferenzierungs assoziierten gens (mda-7) zur umwandlung eines krebsphänotyps
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
DK0873332T3 (da) Discodermolidforbindelser samt farmaceutiske sammensætninger indeholdende dem til cancerterapi
ATE420192T1 (de) Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
FI943750A0 (fi) Menetelmä nekroositekijän valmistamiseksi
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
ES8705521A1 (es) Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos.
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
DE3477791D1 (en) Nucleoside process
DE69332688D1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
HUT61202A (en) Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells
EP0325191A3 (en) Composition and method for protecting against diseases caused by microorganisms
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
WO1997014712A3 (de) Sulfamat-derivate von 1,3,5(10)-estratrien-derivaten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
EA200000522A1 (ru) 5-htагонисты
ATE449172T1 (de) Säugetiergene, die an der viralen infektion beteiligt sind
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
EP0255717A3 (de) Gangliosid-Derivate und Verfahren zur Herstellung davon
AU3300797A (en) Selenophene anti-tumor agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties